Reference change value for α-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease

Clinical Chemistry

Volumn 49, Issue 7, 2003, Pages 1209-1211

  Trapé, Jaume ^a   Botargues, Josep M ^a   Porta, Francesc ^a   Ricós, Carmen ^b   Badal, Josep M ^a   Salinas, Ramon ^a   Sala, Maria ^a   Roca, Angels ^a  

^a Althaia   (Spain)

^b Laboratoris Clinics Hosp Vall d'H   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; BIOASSAY; BLOOD SAMPLING; CALCULATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COLON ADENOCARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE SEVERITY; EARLY DIAGNOSIS; EVALUATION; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PATIENT MONITORING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUALITY CONTROL; SAMPLE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMILUMINESCENT MEASUREMENTS; ELECTRICITY; FEMALE; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 0038271932     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.7.1209     Document Type: Article

References (26)

1. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. Hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
2. Johnson PJ, Williams R. Cirrhosis and aetiology of hepatocellular carcinoma. J Hepatol 1987;4:140-7.
3. Imberti D, Fomari F, Sbolli G, Buscarini E, Squassante L, Buscarini L. Hepatocellular carcinoma in liver cirrhosis. A prospective study. Scand J Gastroenterol 1993;28:540-4.
4. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.
5. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, et al. Utility of α-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 Western patients. Hepatogastroenterology 2000;47:1654-8.
6. Harris EK, Brown SS. Temporal changes in the concentration of serum constituents in healthy men. Distributions of within-person variances and their relevance to the interpretation of differences between successive measurements. Ann Clin Biochem 1979;16:169-76.
7. Queraltó JM, Boyd JC, Harris EK. On the calculation of reference change values, with examples from long-term study. Clin Chem 1993;39:1398-403.
8. Harris EK, Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem 1983;29:25-30.
9. Philipou G, Philips PJ. Intraindividual variation of glycohemoglobin: implications for interpretation and analytical goals. Clin Chem 1993;39:2305-8.
10. Hölzel WGE, Beer R, Deschner W, Griesmacher A, Müller MM. Individual reference ranges of CA15-3, MCA and CEA in recurrence of breast cancer. Scand J Clin Lab Invest Suppl 1995;221:93-101.
11. Panteghini M Pagani F, Bonora R. Pre-analytical and biological variability of prostatic acid phosphatase and prostate specific antigen in serum from patients with prostatic pathology. Eur J Clin Chem Clin Biochem 1992;30:135-9.
12. Mora J, Queraltó JM. Within-subject variation of carcinoembryonic antigen in colorectal cancer - application of reference change values and individual reference ranges to patient follow-up. Eur J Clin Chem Clin Biochem 1997;35:453-7.
13. 1c in patients with type 2 diabetes mellitus. Clin Chem Lab Med 2000;38:1283-7.
14. Kilpatrick EB, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998;21:261-4.
15. Biosca C, Ricós C, Jimenez CV, Lauzurica R, Galimany R. Model for establishing biological variation in non-healthy situations: renal posttransplantation data. Clin Chem 1997;43:2206-8.
16. Kuwahara T, Bakai T, Majima Y, Hirai Y, Tanikawa K. Serial changes in serum α-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis. Hepatogastroenterology 1993;40:347-51.
17. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncol Suppl 2002;63:57-63.
18. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
19. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of α-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002;36:410-7.
20. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422-34.
21. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
22. Ricós C, Baadenhuijsen H, Libeer CJ, Petersen PH, Stockl D, Thienpont L, et al. External quality assessment: currently used criteria for evaluating performance in European countries, and criteria for future harmonization. Eur J Clin Chem Clin Biochem 1996;34:159-65.
23. Fraser CG. General strategies to set quality specifications for reliability performance characteristics. Scand J Clin Lab Invest 1999;59:487-90.
24. Harris EK, Boyd JC. Statistical bases of reference change values in laboratory medicine. New York: Marcel Dekker, 1995:221-58.
25. Kenny D, Fraser CG, Petersen PH, Kallner A. Consensus agreement. Scand J Clin Lab Invest 1999;59:585.
26. Ricós C, Alvarez V, Cava F, Garcia-Lario JV, Hernández A, Jiménez CV, et al. Desirable specifications for total error, and bias, derived from biologic variation. in http://www.westgard.com/biodatabase1.htm (Accessed December 2002).